Augustine Kunle Obisesan

Array ( [id] => 15099441 [patent_doc_number] => 10471014 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-11-12 [patent_title] => Pharmaceutical compositions comprising meloxicam [patent_app_type] => utility [patent_app_number] => 16/001697 [patent_app_country] => US [patent_app_date] => 2018-06-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 11 [patent_no_of_words] => 18809 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 40 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16001697 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13276509 [patent_doc_number] => 10149820 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-12-11 [patent_title] => Compositions and methods for treating pterygium [patent_app_type] => utility [patent_app_number] => 15/991698 [patent_app_country] => US [patent_app_date] => 2018-05-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 10 [patent_no_of_words] => 10493 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 45 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15991698 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13276507 [patent_doc_number] => 10149819 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-12-11 [patent_title] => Compositions and methods for treating hyperemia [patent_app_type] => utility [patent_app_number] => 15/991382 [patent_app_country] => US [patent_app_date] => 2018-05-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 10 [patent_no_of_words] => 10441 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 42 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15991382 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15306371 [patent_doc_number] => 10517866 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-12-31 [patent_title] => Removing senescent cells from a mixed cell population or tissue using a phosphoinositide 3-kinase (PI3K) inhibitor [patent_app_type] => utility [patent_app_number] => 15/981696 [patent_app_country] => US [patent_app_date] => 2018-05-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 72 [patent_figures_cnt] => 120 [patent_no_of_words] => 70139 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 74 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15981696 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14132249 [patent_doc_number] => 20190100514 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-04-04 [patent_title] => METHODS OF TREATING CANCER [patent_app_type] => utility [patent_app_number] => 15/979916 [patent_app_country] => US [patent_app_date] => 2018-05-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 44339 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15979916 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13410053 [patent_doc_number] => 20180256569 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-09-13 [patent_title] => SUBSTITUTED 6,7-DIHYDROPYRAZOLO[1,5-a]PYRAZINES AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS [patent_app_type] => utility [patent_app_number] => 15/976037 [patent_app_country] => US [patent_app_date] => 2018-05-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27515 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15976037 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15099547 [patent_doc_number] => 10471068 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-11-12 [patent_title] => Pharmaceutical compositions comprising meloxicam [patent_app_type] => utility [patent_app_number] => 15/976800 [patent_app_country] => US [patent_app_date] => 2018-05-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 11 [patent_no_of_words] => 16854 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 148 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15976800 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15006163 [patent_doc_number] => 10449186 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-10-22 [patent_title] => Phenylethynyl-substituted benzenes and heterocycles for the treatment of cancer [patent_app_type] => utility [patent_app_number] => 15/976643 [patent_app_country] => US [patent_app_date] => 2018-05-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 3 [patent_no_of_words] => 10580 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 100 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15976643 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14849715 [patent_doc_number] => 10413563 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-09-17 [patent_title] => Neurochemical wellness program [patent_app_type] => utility [patent_app_number] => 15/974909 [patent_app_country] => US [patent_app_date] => 2018-05-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 4212 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 32 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15974909 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13548607 [patent_doc_number] => 20180325851 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-11-15 [patent_title] => Transdermally-Delivered Combination Drug Therapy for Pain [patent_app_type] => utility [patent_app_number] => 15/974796 [patent_app_country] => US [patent_app_date] => 2018-05-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14308 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 94 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15974796 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13586387 [patent_doc_number] => 20180344742 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-12-06 [patent_title] => METHOD FOR PROMOTING WOUND HEALING BY ADMINISTERING A COMPOUND WHICH BINDS LDL-RECEPTOR-RELATED PROTEIN (LRP) LIGAND BINDING DOMAIN [patent_app_type] => utility [patent_app_number] => 15/974759 [patent_app_country] => US [patent_app_date] => 2018-05-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9499 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 37 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15974759 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15243379 [patent_doc_number] => 10507199 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-12-17 [patent_title] => Molecules in the tryptophan-5-hydroxytryptophan-serotonin-NAS-melatonin/6-hydroxymelatonin sulfate-melatonin receptor 1A pathway in neurological diseases [patent_app_type] => utility [patent_app_number] => 15/974184 [patent_app_country] => US [patent_app_date] => 2018-05-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 38 [patent_no_of_words] => 15535 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 81 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15974184 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14306251 [patent_doc_number] => 20190142829 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-05-16 [patent_title] => AMELIORATION OF ANGELMAN'S SYNDROME DEFICIENCIES [patent_app_type] => utility [patent_app_number] => 15/961419 [patent_app_country] => US [patent_app_date] => 2018-04-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 2316 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 40 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15961419 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14099111 [patent_doc_number] => 20190091231 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-03-28 [patent_title] => METHODS OF TREATING DEVELOPMENTAL DISORDERS AND/OR SEIZURE DISORDERS WITH ETIFOXINE [patent_app_type] => utility [patent_app_number] => 15/961002 [patent_app_country] => US [patent_app_date] => 2018-04-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12770 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15961002 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15632011 [patent_doc_number] => 10588973 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-03-17 [patent_title] => Percutaneous absorption composition [patent_app_type] => utility [patent_app_number] => 15/960392 [patent_app_country] => US [patent_app_date] => 2018-04-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4582 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 57 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15960392 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15493103 [patent_doc_number] => 20200046740 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-02-13 [patent_title] => TARGETING HYPOXIC CANCER STEM CELLS (CSCS) WITH DOXYCYCLINE: IMPLICATIONS FOR IMPROVING ANTI-ANGIOGENIC THERAPY [patent_app_type] => utility [patent_app_number] => 16/606849 [patent_app_country] => US [patent_app_date] => 2018-04-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4747 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 26 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16606849 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13368833 [patent_doc_number] => 20180235957 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-08-23 [patent_title] => Treatment of Ophthalmic Conditions by Selectively Removing Senescent Cells from the Eye [patent_app_type] => utility [patent_app_number] => 15/956613 [patent_app_country] => US [patent_app_date] => 2018-04-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 70177 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 95 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15956613 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13563719 [patent_doc_number] => 20180333407 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-11-22 [patent_title] => Methods Of Safely Transitioning A Subject To Buprenorphine [patent_app_type] => utility [patent_app_number] => 15/955532 [patent_app_country] => US [patent_app_date] => 2018-04-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11336 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15955532 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14169263 [patent_doc_number] => 10258618 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-04-16 [patent_title] => Treating pulmonary conditions by selectively removing senescent cells from the lung using an intermittent dosing regimen [patent_app_type] => utility [patent_app_number] => 15/955542 [patent_app_country] => US [patent_app_date] => 2018-04-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 72 [patent_figures_cnt] => 120 [patent_no_of_words] => 70198 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 107 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15955542 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13746559 [patent_doc_number] => 10166204 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-01-01 [patent_title] => Sphingosine kinase type 1 inhibitors and uses thereof [patent_app_type] => utility [patent_app_number] => 15/954131 [patent_app_country] => US [patent_app_date] => 2018-04-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 19 [patent_figures_cnt] => 42 [patent_no_of_words] => 16687 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 27 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15954131 [rel_patent_id] =>[rel_patent_doc_number] =>)